A Trial of ZL-1201 in Subjects With Advanced Cancer

• Status: Recruiting
• Trial end date: 2024-01-31
• Target enrollment: 0
• Participant gender: All

Summary

First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.
• Collaborator: PPD
• Treatments: Antibodies

Criteria

Inclusion Criteria:

• Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors and lymphomas that are refractory or intolerant to standard of care therapy, or for which no standard therapy exists.

• Adequate hematologic status

• Adequate coagulation function

• Adequate hepatic function

• Adequate renal function

Exclusion Criteria:

• Known active brain metastases

• Red blood cells transfusion dependence

• Known cardiopulmonary disease

• Pregnant or breast-feeding females

• Any other serious underlying medical